Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals faces a surge of institutional buying amid a steeply negative P/E, raising questions about hidden value or speculative risk.

Avadel Pharmaceuticals faces a $2.1 bn Alkermes takeover and heavy institutional activity—learn how this could reshape its valuation and volatility.

Avadel Pharmaceuticals sees a surge of institutional interest—BlackRock, Citadel, Vanguard, and others stake 13‑15% as Lundbeck and Alkermes battle over its sleep‑disorder portfolio, potentially reshaping its $2.25 billion valuation.

Avadel Pharmaceuticals: BlackRock, Vanguard and Wells Fargo lift interest as institutional stakes rise, analyst targets hit $20, and the stock nears a 52‑week high—what does this mean for investors?

Avadel Pharmaceuticals sees a surge of institutional buying, with 14 funds reporting stakes in a volatile specialty‑drug stock that’s still loss‑making but near a 52‑week high. Read why big players may signal a turning point for this $1.84 billion c…

Avadel Pharmaceuticals, a specialty pharmaceutical company, is facing significant financial challenges, including a negative price-to-earnings ratio and stock price volatility, which raises concerns about its financial stability and investor confide…

Avadel Pharmaceuticals faces a tumultuous period, balancing a recent legal victory with a boardroom battle and investor concerns over governance and financial stability.

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company that has carved a niche in the healthcare industry by focusing on innovative treatments for chronic urological, central nervous system, and sleep disorders.

Avadel Pharmaceuticals’ stock price surged after a court victory allowed the company to expand trials for its medication LUMRYZ, treating Idiopathic Hypersomnia and narcolepsy.

Avadel Pharmaceuticals PLC’s stock surged after a court victory allowed the company to expand trials for its drug LUMRYZ, boosting its growth prospects and revenue potential.